Security
Gyre Therapeutics, Inc. Common Stock · GYRE
GYRENASDAQCommon stockCurrentCIK 1124105Updated Nov 7, 2026
Name history
CATALYST BIOSCIENCES, INC. · through Oct 27, 2023TARGACEPT INC · through Aug 19, 2015
GYRE price & chart
Loading TradingView…
NASDAQ:GYRE on TradingView ↗About the company
Gyre Pharmaceuticals Co., Ltd., a subsidiary of Gyre Therapeutics, Inc., is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing, and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY™ (pirfenidone capsule), was the first approved treatment in 2011 for idiopathic pulmonary fibrosis (IPF) in the PRC. Gyre Pharmaceuticals' pipeline includes F351 (hydronidone), a structural analogue of pirfenidone, which has received Breakthrough Therapy designation by the CDE of the NMPA in March 2021 and is currently under review by the NMPA for a New Drug Application (NDA) for the treatment of CHB-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus (HBV). Gyre Pharmaceuticals is leveraging the pirfenidone-platform to develop treatments for pneumoconiosis and RILI with or without immune-related pneumonitis. Our expertise in pirfenidone compounds has allowed us to expand development programs with F528 for the treatment of chronic obstructive pulmonary disease (COPD), F230 in development for the treatment of pulmonary arterial hypertension (PAH), and F573 in development fo…
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
S-8 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 159,384,000Source | 125,240,000Source | 199,255,000Source | 152,646,000Source | 120,929,000Source | 162,015,000Source | 129,790,000Source | 122,010,000Source | 166,132,000Source | 125,406,000Source | 116,539,000Source | 28,444,000Source |
| Property, Plant and Equipment, NetUSD | 23,608,000Source | 24,442,000Source | 27,284,000Source | 23,401,000Source | 23,672,000Source | 23,572,000Source | 23,518,000Source | 23,564,000Source | 23,599,000Source | 23,880,000Source | 23,288,000Source | 4,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 40,402,000Source | 15,866,000Source | 43,287,000Source | 36,491,000Source | 16,097,000Source | 37,501,000Source | 15,045,000Source | 29,785,000Source | 37,070,000Source | 11,813,000Source | 33,509,000Source | 21,666,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 25,877,000Source | — | 27,760,000Source | 24,629,000Source | — | 22,763,000Source | 20,150,000Source | — | 31,078,000Source | 19,589,000Source | — | — |
| Inventory, NetUSD | — | 6,379,000Source | 11,428,000Source | 8,861,000Source | 5,635,000Source | 11,352,000Source | 7,878,000Source | 4,939,000Source | — | 6,337,000Source | 4,281,000Source | — |
| Assets, CurrentUSD | 98,576,000Source | 54,809,000Source | 122,072,000Source | 91,285,000Source | 53,519,000Source | 91,732,000Source | 68,448,000Source | 62,723,000Source | 102,369,000Source | 64,786,000Source | 57,221,000Source | 28,206,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,873,000Source | — | 7,601,000Source | 2,701,000Source | — | 3,762,000Source | 8,161,000Source | — | — | — | — | 1,540,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,300,000Source | 1,984,000Source | 3,279,000Source | 1,500,000Source | 2,097,000Source | 2,400,000Source | 1,600,000Source | 359,000Source | 1,131,000Source | 1,818,000Source | 489,000Source | 66,000Source |
| Other Assets, NoncurrentUSD | 5,322,000Source | 2,766,000Source | 7,344,000Source | 5,336,000Source | 1,278,000Source | 4,942,000Source | 5,556,000Source | 802,000Source | 2,492,000Source | 3,030,000Source | 995,000Source | 168,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 21,969,000Source | 26,766,000Source | 34,336,000Source | 23,203,000Source | 27,583,000Source | 25,030,000Source | 25,488,000Source | 33,239,000Source | 23,850,000Source | 27,004,000Source | 38,065,000Source | 16,824,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 91,000Source | 85,000Source | 106,000Source | 91,000Source | 85,000Source | 91,000Source | 87,000Source | 85,000Source | 91,000Source | 86,000Source | 77,000Source | 37,000Source |
| Additional Paid in CapitalUSD | 167,134,000Source | 134,296,000Source | 240,644,000Source | 161,437,000Source | 133,656,000Source | 174,651,000Source | 138,179,000Source | 133,199,000Source | 172,047,000Source | 136,185,000Source | 68,179,000Source | 389,210,000Source |
| Retained Earnings (Accumulated Deficit)USD | -66,703,000Source | -73,354,000Source | -137,962,000Source | -70,313,000Source | -74,478,000Source | -77,667,000Source | -70,755,000Source | -78,006,000Source | -68,426,000Source | -73,453,000Source | -85,538,000Source | -410,936,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,700,000Source | -946,000Source | 1,492,000Source | -2,287,000Source | -2,010,000Source | 586,000Source | -2,486,000Source | -1,736,000Source | -779,000Source | -2,597,000Source | -1,644,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 101,920,000Source | 63,179,000Source | 107,928,000Source | 92,026,000Source | 60,351,000Source | 101,309,000Source | 68,123,000Source | 56,640,000Source | 106,031,000Source | 63,319,000Source | -15,828,000Source | -21,689,000Source |
| Liabilities and EquityUSD | 159,384,000Source | 125,240,000Source | 199,255,000Source | 152,646,000Source | 120,929,000Source | 162,015,000Source | 129,790,000Source | 122,010,000Source | 166,132,000Source | 125,406,000Source | 116,539,000Source | 28,444,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 15,913,000Source | 14,716,000Source | 28,663,000Source | 16,920,000Source | 15,574,000Source | 19,788,000Source | 18,991,000Source | 19,486,000Source | 18,286,000Source | 19,516,000Source | 20,047,000Source | 16,824,000Source |
| Operating Lease, Liability, CurrentUSD | 626,000Source | 694,000Source | 1,385,000Source | 622,000Source | 659,000Source | 751,000Source | 805,000Source | 100,000Source | 636,000Source | 713,000Source | 210,000Source | 38,000Source |
| Accounts Payable, CurrentUSD | 556,000Source | 303,000Source | 1,236,000Source | 71,000Source | 271,000Source | 265,000Source | 122,000Source | 330,000Source | 124,000Source | 108,000Source | 355,000Source | 194,000Source |
| Operating Lease, Liability, NoncurrentUSD | 539,000Source | 1,101,000Source | 2,033,000Source | 771,000Source | 1,297,000Source | 72,000Source | 780,000Source | 175,000Source | 303,000Source | 885,000Source | 199,000Source | — |
| Other Liabilities, NoncurrentUSD | 1,427,000Source | 2,000Source | 70,000Source | 1,427,000Source | 47,000Source | 1,458,000Source | 1,399,000Source | 48,000Source | 1,448,000Source | 7,000Source | 49,000Source | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 35,495,000Source | 35,295,000Source | 34,561,000Source | 37,417,000Source | 32,995,000Source | 35,676,000Source | 36,179,000Source | 32,131,000Source | 36,251,000Source | 35,083,000Source | 29,777,000Source | — |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 33,500,000Source | 21,700,000Source |
| Deferred Revenue, CurrentUSD | — | 36,000Source | — | — | 57,000Source | — | — | 35,000Source | — | — | 39,000Source | — |
| Deferred Revenue, NoncurrentUSD | 866,000Source | 185,000Source | 829,000Source | 884,000Source | 192,000Source | 840,000Source | 905,000Source | 203,000Source | 852,000Source | 928,000Source | 213,000Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 9,600,000Source | 8,300,000Source | 2,500,000Source | — |
| Dividends Payable, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 7,558,000Source |
| Short-term InvestmentsUSD | 19,647,000Source | 9,226,000Source | 14,058,000Source | 17,874,000Source | 9,003,000Source | 12,307,000Source | 14,846,000Source | 7,567,000Source | 15,355,000Source | 14,858,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -9,858,000Source | 3,734,000Source | 9,880,000Source | 17,898,000Source | -85,480,000Source | -8,242,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 672,000Source | 535,000Source | 2,481,000Source | 1,549,000Source | 1,074,000Source | 230,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,583,000Source | 507,000Source | 7,157,000Source | 831,000Source | 7,281,000Source | 1,342,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -8,573,000Source | 722,000Source | 10,806,000Source | 5,257,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 1,015,000Source | 1,541,000Source | 3,631,000Source | 2,139,000Source | -1,747,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 139,000Source | 14,000Source | 13,000Source | -245,000Source | 192,000Source | -6,225,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -1,108,000Source | -1,002,000Source | -834,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 3,180,000Source | -129,000Source | 1,010,000Source | -3,641,000Source | 25,892,000Source | -33,096,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -3,055,000Source | 1,967,000Source | -474,000Source | -19,884,000Source | -19,760,000Source | 55,426,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 178,000Source | 122,000Source | 1,190,000Source | 2,315,000Source | 8,517,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 21,000Source | 1,344,000Source | 24,378,000Source | 2,102,000Source | 2,500,000Source | -45,011,000Source |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 431,000Source | 3,232,000Source | 25,257,000Source | -21,696,000Source | 8,334,000Source | -22,681,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 1,214,000Source | 3,359,000Source | 5,621,000Source | 8,518,000Source | 6,346,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,147,000Source | 237,000Source | 1,833,000Source | 1,120,000Source | 2,583,000Source | 507,000Source | 7,157,000Source | 831,000Source | 7,281,000Source | 1,342,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | 2,000Source | — | 9,000Source | — | — |
| Amortization of Intangible AssetsUSD | — | — | 170,000Source | 10,000Source | 179,000Source | 167,000Source | 175,000Source | 67,000Source | 576,000Source | 38,000Source | 100,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 33,500,000Source | 21,700,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| DepreciationUSD | — | — | — | — | 1,100,000Source | 800,000Source | — | — | 2,000,000Source | 1,300,000Source | 1,000,000Source | — |
| Dividends Payable, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 7,558,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | -1,000Source | — | — | -1,000Source | — | — | -4,000Source | — | — | 57,186,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | — | — | — | — | -2,711,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | -16,000Source | — | -4,000Source | -66,000Source | -628,000Source | — |
| General and Administrative ExpenseUSD | — | — | 4,319,000Source | 3,823,000Source | 7,867,000Source | 7,277,000Source | 7,220,000Source | 4,955,000Source | 20,804,000Source | 16,109,000Source | 14,662,000Source | 17,366,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 5,936,000Source | 2,856,000Source | -14,270,000Source | -2,237,000Source | -9,858,000Source | 3,734,000Source | 9,880,000Source | 17,898,000Source | -85,480,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 1,693,000Source | 1,074,000Source | -164,000Source | 662,000Source | 621,000Source | 901,000Source | 4,556,000Source | 5,320,000Source | 8,515,000Source | 348,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 5,936,000Source | 2,856,000Source | -14,270,000Source | -2,237,000Source | -9,858,000Source | 3,734,000Source | 9,880,000Source | 17,898,000Source | -85,480,000Source | -8,242,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 2,326,000Source | 1,732,000Source | -3,665,000Source | -2,835,000Source | -1,167,000Source | 1,036,000Source | 4,853,000Source | 5,813,000Source | 7,453,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 3,610,000Source | 1,124,000Source | -11,663,000Source | -2,044,000Source | -8,691,000Source | 2,698,000Source | 5,027,000Source | 12,085,000Source | -92,933,000Source | — |
| Operating ExpensesUSD | — | — | 22,011,000Source | 20,297,000Source | 43,463,000Source | 31,972,000Source | 31,874,000Source | 19,785,000Source | 105,101,000Source | 85,710,000Source | 176,044,000Source | 9,405,000Source |
| Operating Lease, ExpenseUSD | — | — | 200,000Source | 300,000Source | 400,000Source | 500,000Source | 200,000Source | 200,000Source | 900,000Source | 700,000Source | 500,000Source | 1,700,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 727,000Source | -75,000Source | -943,000Source | -488,000Source | 29,000Source | 107,000Source | -1,505,000Source | -1,659,000Source | — | — |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | 121,000Source | 1,487,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 509,000Source | — | 773,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 21,000Source | 956,000Source | 2,356,000Source | 1,865,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | 105,757,000Source | 113,450,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 30,564,000Source | 25,488,000Source | 29,105,000Source | 29,734,000Source | 22,519,000Source | 22,058,000Source | 116,588,000Source | 105,757,000Source | 113,450,000Source | — |
| Cost of RevenueUSD | — | — | 1,628,000Source | 958,000Source | 2,209,000Source | 1,151,000Source | 1,227,000Source | 894,000Source | 5,416,000Source | 3,884,000Source | 4,636,000Source | — |
| Operating Income (Loss)USD | — | — | 6,925,000Source | 4,233,000Source | -14,363,000Source | -2,240,000Source | -9,355,000Source | 2,273,000Source | 11,487,000Source | 16,163,000Source | -67,230,000Source | -8,611,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 727,000Source | -75,000Source | -943,000Source | -488,000Source | 29,000Source | 107,000Source | -1,505,000Source | -1,659,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 7,629,000Source | 3,930,000Source | -14,434,000Source | -1,575,000Source | -9,237,000Source | 4,635,000Source | 14,436,000Source | 23,218,000Source | -76,965,000Source | -7,894,000Source |
| Income Tax Expense (Benefit)USD | — | — | 1,693,000Source | 1,074,000Source | -164,000Source | 662,000Source | 621,000Source | 901,000Source | 4,556,000Source | 5,320,000Source | 8,515,000Source | 348,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 2,326,000Source | 1,732,000Source | -3,665,000Source | -2,835,000Source | -1,167,000Source | 1,036,000Source | 4,853,000Source | 5,813,000Source | 7,453,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 5,936,000Source | 2,856,000Source | -14,270,000Source | -2,237,000Source | -9,858,000Source | 3,734,000Source | 9,880,000Source | 17,898,000Source | -85,480,000Source | -8,242,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.04Source | 0.01Source | -0.12Source | -0.02Source | -0.1Source | 0.03Source | 0.06Source | 0.14Source | -1.41Source | -0.26Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.03Source | 0.01Source | -0.12Source | -0.03Source | -0.1Source | 0Source | 0.02Source | 0.05Source | -1.41Source | -0.26Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 90,850,040Source | 85,643,646Source | 100,637,599Source | 89,119,344Source | 91,317,142Source | 86,420,530Source | 89,344,622Source | 85,094,948Source | 65,831,675Source | 31,545,723Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 103,971,546Source | 102,640,373Source | 100,637,599Source | 89,203,138Source | 91,344,584Source | 101,970,672Source | 103,180,037Source | 102,293,526Source | 65,831,675Source | 31,545,723Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 170,000Source | 10,000Source | 179,000Source | 167,000Source | 175,000Source | 67,000Source | 576,000Source | 38,000Source | 100,000Source | — |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | — | — | — | — | — | 0.24Source |
| Costs and ExpensesUSD | — | — | 23,639,000Source | 21,255,000Source | 43,468,000Source | 31,974,000Source | 31,874,000Source | 19,785,000Source | 105,101,000Source | 89,594,000Source | 180,680,000Source | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 5,664,000Source | 6,322,000Source | 9,349,000Source | — |
| General and Administrative ExpenseUSD | — | — | 4,319,000Source | 3,823,000Source | 7,867,000Source | 7,277,000Source | 7,220,000Source | 4,955,000Source | 20,804,000Source | 16,109,000Source | 14,662,000Source | 17,366,000Source |
| Gross ProfitUSD | — | — | 28,936,000Source | 24,530,000Source | — | 25,620,000Source | — | 21,164,000Source | — | 101,873,000Source | 108,814,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -5,191,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 5,936,000Source | 2,856,000Source | -14,270,000Source | -2,237,000Source | -9,858,000Source | 3,734,000Source | 9,880,000Source | 17,898,000Source | -85,480,000Source | — |
| Interest Income (Expense), NetUSD | — | — | — | 523,000Source | 740,000Source | 941,000Source | — | — | 1,747,000Source | 1,547,000Source | 1,044,000Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 537,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 3,610,000Source | 1,124,000Source | -11,663,000Source | -2,044,000Source | -8,691,000Source | 2,698,000Source | 5,027,000Source | 12,085,000Source | -92,933,000Source | — |
| Operating ExpensesUSD | — | — | 22,011,000Source | 20,297,000Source | 43,463,000Source | 31,972,000Source | 31,874,000Source | 19,785,000Source | 105,101,000Source | 85,710,000Source | 176,044,000Source | 9,405,000Source |
| Operating Lease, ExpenseUSD | — | — | 200,000Source | 300,000Source | 400,000Source | 500,000Source | 200,000Source | 200,000Source | 900,000Source | 700,000Source | 500,000Source | 1,700,000Source |
| Research and Development ExpenseUSD | — | — | 2,363,000Source | 2,775,000Source | — | 8,351,000Source | 6,738,000Source | 3,095,000Source | 13,698,000Source | 12,024,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | 105,757,000Source | 113,450,000Source | — |
| Selling and Marketing ExpenseUSD | — | — | 15,328,000Source | 13,699,000Source | 13,754,000Source | 15,195,000Source | 14,136,000Source | 10,841,000Source | 65,179,000Source | 57,511,000Source | 61,159,000Source | — |
| Selling, General and Administrative Expense | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Other General and Administrative Expense | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-296957
Filing attachments
gyre-ex99_1.htm · 8-K · 2026-11-05
Exhibit 99.1 Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, November 5, 2026 -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), a U.S. biopharmaceutical company with research operations and commercial business in China to advance global development of protein degrader t…
Read attachment ↗gyre-ex99_2.htm · 8-K · 2026-11-05
1 November 2026 A Global Innovator Expanding And Reinventing Protein Degrader Therapeutics This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding the current plans, expectations and strategies of Gyre Therapeutics, Inc. and its subsidiaries (“Gyre”), which statements are subject to substan…
Read attachment ↗ef20081441_ex99-1.htm · 8-K · 2026-09-01
EX-99.1 2 ef20081441_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 September 2026 A Global Innovator Expanding And Reinventing Protein Degrader Therapeutics This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding the current plans, expectations and strategies of Gyre Therapeutics, Inc. and it…
Read attachment ↗ef20081105_ex107.htm · S-8 · 2026-08-31
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) Gyre Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Maximum Aggregate Fee Rate Amount of Registration Fee …
Read attachment ↗ef20081104_ex99-1.htm · 8-K · 2026-08-26
EX-99.1 2 ef20081104_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 August 2026 Building A New Protein Degrader Company For Unmet Medical Needs This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding the current plans, expectations and strategies of Gyre Therapeutics, Inc. and its subsidiaries…
Read attachment ↗gyre-ex99_1.htm · 8-K · 2026-08-07
EX-99.1 2 gyre-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May 2026 SAN DIEGO, August 7, 2026 -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: G…
Read attachment ↗